- Roger Pebody | 29 July 2010
Scientists, lawyers and advocates have been able to reduce
unwarranted prosecutions of HIV exposure and transmission in three European
jurisdictions by employing three distinct approaches, Robert James told the
Eighteenth International AIDS Conference ...
- Roger Pebody | 28 July 2010
In the countries of Eastern Europe and Central Asia, 89% of
national government funding for HIV prevention goes on programmes for the
general population, although most countries’ epidemics are dominated by
injecting drug ...
- Mara Kardas-Nelson | 27 July 2010
Two scientific lectures presented at the
Eighteenth International AIDS Conference in Vienna last week,
demonstrated that drug use in and of itself is linked to increased rates of HIV
transmission, giving support ...
- Mara Kardas-Nelson | 27 July 2010
Drug policies based on ideology rather than
science are fueling human rights abuses of drug users, according to a panel of
experts speaking at last week’s Eighteenth International AIDS Conference which
took place ...
- Rebecca Hodes | 27 July 2010
At the International AIDS Conference in Vienna, a session on the financing of HIV programmes yielded important results about the long-term costs and health
impacts of continued Global Fund financing of ...
- Roger Pebody | 27 July 2010
South Africa’s campaign to test 15 million
people for HIV in one year risks being implemented in a way that undermines
people’s human rights, the activist Mark Heywood told the Eighteenth
International AIDS ...
- Liz Highleyman | 26 July 2010
Combination antiretroviral regimens
containing atazanavir (Reyataz) plus
drugs from two newer classes
– the integrase inhibitor raltegravir (Isentress) and the CCR5 antagonist
maraviroc (Celsentri)
– demonstrated
promising anti-HIV activity, but presented some concerns related ...
- Liz Highleyman | 26 July 2010
People who had a low CD4 cell count
in the past remain at greater risk for HIV-related neurocognitive impairment even
after they start antiretroviral therapy and their immune status improves,
participants heard in ...
- Roger Pebody | 26 July 2010
An analysis of transmission patterns in Lilongwe, Malawi
shows that even if a highly effective HIV prevention intervention could reach
75% of people in chronic infection, it would never eliminate the HIV ...
- Liz Highleyman | 23 July 2010
Starting antiretroviral therapy with
a CD4 cell count between 350 and 500 cells/mm3 reduces the
likelihood of HIV disease progression and death relative to initiation below
350 cells/mm3, according to findings from the ...
- Gus Cairns | 23 July 2010
The last day of the Vienna International AIDS Conference featured
the results of the second-ever completed randomised controlled trial of
pre-exposure prophylaxis (PrEP) – giving antiretrovirals to HIV-negative people
at high risk of ...
- Roger Pebody | 23 July 2010
The first
data from new systems of detecting recent HIV infection in the UK have shown
that among those diagnosed, one in six gay men were infected in the past few
months, whereas ...
- Mara Kardas-Nelson | 23 July 2010
A panel at the Eighteenth International AIDS Conference in
Vienna this week recognised the dire level of health need among prisoners and the slow
progress currently being made towards prison health reform. ...
- Theo Smart | 23 July 2010
Starting
antiretroviral therapy (ART) in people with TB and advanced HIV disease two
weeks after starting TB therapy, rather than waiting eight weeks, significantly improves survival
according to the results of the CAMbodian ...
- Liz Highleyman | 23 July 2010
A new extended-release formulation
of nevirapine (Viramune) can be taken
once daily and performs at least as well as the older immediate-release pill,
attendees heard at a late-breaker presentation on Thursday at the ...
- Liz Highleyman | 23 July 2010
The second-generation integrase
inhibitor S/GSK1349572, or GSK-572 for short, continues to demonstrate potent
antiviral activity
– including activity against HIV strains resistant to
raltegravir (Isentress)
– as it prepares to enter Phase III ...
- Carole Leach-Lemens | 22 July 2010
Starting antiretroviral treatment early in HIV-infected infants, at a median
of seven weeks of age, resulted in cost savings of 80%, compared to
deferring treatment until a median age of 29 weeks, ...
- Roger Pebody | 22 July 2010
In Kampala,
Uganda, men who have sex with men who have suffered homophobic violence or abuse are
five times more likely to be HIV-positive than other men, Joseph Barker told
the Eighteenth International ...
- Keith Alcorn | 22 July 2010
The new
Tibotec non-nucleoside reverse transcriptase inhibitor rilpivirine (TMC278) is
just as effective as efavirenz in suppressing viral load, but less likely to
cause side-effects, delegates heard today at the Eighteenth International AIDS
Conference ...
- Gus Cairns | 22 July 2010
Hepatitis C infection amongst HIV-positive gay men attending
an STI clinic in Amsterdam continues to be extremely common, the Eighteenth
International AIDS Conference in Vienna heard. But the growing epidemic of co-infection ...
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...